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Abstract
Constantly evolving treatment guidelines based on a growing body
of randomized controlled trials are helping us to improve outcomes
in sepsis. However, it must be borne in mind that proven benefit
from individual sepsis treatments does not guarantee synergistic
beneficial effects when new treatments are added to sepsis
management. Indeed, unexpected harmful interactions are also
possible. A good example of this is the conflict between intensive
insulin therapy and ‘low dose’ hydrocortisone in septic shock. The
goal of tight glycaemic control is made more complicated by
steroid-induced hyperglycaemia. In their recent study, Loisa and
coworkers demonstrate a measure that reduces the risk for this
interaction. They found continuous infusion of hydrocortisone to be
associated with fewer hyperglycaemic episodes and reduced staff
workload compared with bolus application.
In this issue of Critical Care, Loisa and coworkers [1] present
the first randomized controlled trial on the influence of mode
of hydrocortisone administration on glycaemic control in
patients with septic shock.
During the past few years intensive insulin therapy has come
to be recognized as a key component of treatment of critically
ill patients, with significant impact on morbidity and mortality
[2]. However, it has also been shown that these findings are
not necessarily applicable to all the clinical situations
encountered in critical care [3]. Moreover, there are certain
clinical conditions in which achieving glycaemic control
remains challenging. Clinicians are often faced with widely
varying glucose levels in patients with severe sepsis or septic
shock. Although stress-induced hyperglycaemia and reduced
insulin sensitivity are the primary disorders of glucose
metabolism in severe sepsis, iatrogenic hypoglycaemia - as a
result of intensive insulin therapy - must now also be
reckoned with [4]. It appears that not only high blood glucose
levels but also high glucose variability (range of variation of
greater than 30 to 40 mg/dl) is associated with increased
morbidity and mortality [5]. In this situation ‘low dose’
hydrocortisone (200 to 300 mg/day), which is now
recommended as an adjunctive therapy in septic shock, may
further aggravate problems with glucose control. The
Surviving Sepsis Campaign [6] favours neither bolus nor
continuous administration of hydrocortisone in septic shock
because of the lack of a comparative study. Moreover, a
recent meta-analysis did not demonstrate significant
differences in the risk for hyperglycaemia in septic shock
patients treated with glucocorticoids [7]. However, it must be
stressed that the definitions of hyperglycaemia in septic
patients used in these studies are different from those in
current use (<150 mg/dl) [8].
As their name implies, glucocorticoids affect blood glucose
levels and insulin-dependent glucose uptake by skeletal
muscle via the GLUT-4 glucose transporter. This physio-
logical response in systemic inflammation is aggravated by
the administration of exogenous glucocorticoids [9,10].
Hydrocortisone via continuous infusion results in plasma
cortisol levels of 70 to 140 µg/dl [11], which are significantly
higher that the levels of 40 to 50 µg/dl that are otherwise
measured in patients with septic shock. Notably, peak plasma
cortisol levels measured after intermittent boluses of 50 mg
hydrocortisone (four times a day) considerably exceed these
values (150 to 200 µg/dl) and fluctuate more widely, with
nadir plasma cortisol levels of 40 to 50 µg/dl being reported
[12]. This raises the question of whether bolus hydro-
cortisone therapy unnecessarily complicates glycaemic
control in what is an already difficult situation.
In addressing this question, the study by Loisa and coworkers
[1] is important and merits prominence. They conducted a
prospective study in 48 septic shock patients, who were
randomly assigned to receive either four times daily 50 mg
hydrocortisone boluses or the same dosage as a continuous
infusion. Blood glucose was recorded every 2 hours and
insulin titrated to blood glucose levels of 4 to 7 mmol/l (72 to
126 mg/dl). The frequency of insulin adjustments was
documented and used as a measure of staff workload. One
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major finding was that significantly more episodes of
hyperglycaemia (>126 mg/dl) occurred in the bolus group,
although episodes of severe hyperglycaemia (>150 mg/dl)
were rare and not significantly more frequent in either group.
So, why worry about the mode of application? Recent results
of an observational study on the responses to these two
modes of hydrocortisone application showed marked inter-
individual variation and increases in blood glucose to levels
above 150 mg/dl in the majority of patients when intermittent
boluses were used [13]. Importantly, the baseline mean blood
glucose values before hydrocortisone bolus application were
considerably higher (about 130 mg/dl) in this study than in
the one conducted by Loisa and coworkers [1]. Because
tight glycaemic control (80 to 110 mg/dl) is not currently
recommended in sepsis, we contend that the glucose levels
encountered in our study [13] were closer to those one
would expect to observe in current routine practice. We
previously speculated that fluctuations in blood glucose
would require more frequent insulin dose adjustments. This
was now been prospectively demonstrated by Loisa and
coworkers [1], who demonstrated a significant increase in
staff workload during bolus hydrocortisone application.
Although the study did not demonstrate an impact on
mortality, it is questionable whether a sufficiently powered
study to address this question will ever be performed. As the
range of therapies available to physicians treating sepsis
widens, so too does the potential for adverse pharmaco-
logical events, and interactions in particular. Investigations
such as this by Loisa and coworkers are vital if we are to
ensure that the increasingly complex management of sepsis
remains safe.
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